Evidence map›Paper›PMID 37046288›Full record

ArticleVirology journal2023

Influenza vaccine effectiveness in patients hospitalized with severe acute respiratory infection in Lithuania during the 2019-2020 influenza season: a test negative case - control study.

Roberta Vaikutyte, Monika Kuliese, Aukse Mickiene, Ligita Jancoriene, Birute Zablockiene, Giedre Gefenaite, Study group

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Roberta VaikutyteDepartment of Infectious Diseases, Lithuanian University of Health Sciences, Baltijos Street 120, Kaunas, 47116, Lithuania. roberta.vaikutyte@lsmu.lt.
Monika KulieseDepartment of Infectious Diseases, Lithuanian University of Health Sciences, Baltijos Street 120, Kaunas, 47116, Lithuania.
Aukse MickieneDepartment of Infectious Diseases, Lithuanian University of Health Sciences, Baltijos Street 120, Kaunas, 47116, Lithuania.
Ligita JancorieneClinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu street 14, Vilnius, 08406, Lithuania.
Birute ZablockieneClinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu street 14, Vilnius, 08406, Lithuania.
Giedre GefenaiteDepartment of Infectious Diseases, Lithuanian University of Health Sciences, Baltijos Street 120, Kaunas, 47116, Lithuania.
Study group
Lithuanian University of Health Sciences · LTVilnius University · LTVilnius University Hospital Santariskiu Klinikos · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza is a contagious viral airborne disease that adds to the clinical and economic burden on the healthcare system. It could be prevented substantially by seasonal influenza vaccination. Seasonal influenza vaccine effectiveness (SIVE) varies a lot and should therefore be monitored. This report aims to update age-stratified SIVE estimates among patients hospitalized due to severe acute respiratory infection (SARI) during the 2019-2020 influenza season.

methodsWe performed a test-negative case-control study between December 2019 and April 2020 influenza season. We estimated SIVE and its 95% confidence intervals (95% CI) with logistic regression as (1-odds ratio)*100%. The models were adjusted for covariates that changed the unadjusted SIVE by ≥ 10%.

resultsAmong 84 participants, 32 (38.1%) were influenza positive, mostly with A(H1N1)pdm09 (25 cases; 78.1%). SIVE against any influenza adjusted for age and heart disease was 39.2% (95% CI: -119.3%, 83.1%). Age-stratified point estimates adjusted for heart diseases indicated different SIVE, and were 64.0% (95% CI: -309.2%, 96.8%) and 21.6% (95% CI: -252.2%, 82.6%) for 18-64 and ≥ 65 year-old participants, respectively.

conclusionsThe point estimates suggested low to moderate SIVE against any influenza among hospitalized 18-64-year-old SARI participants, while low estimates were found in the ≥ 65-year-old group. Although broad SIVE confidence intervals indicate a small sample size and therefore the results can serve only as indicatory, they are in line with the estimates reported by other studies during the 2019-2020 season.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesAdolescentAdultAgedCase-Control StudiesHumansInfluenza A Virus, H3N2 SubtypeInfluenza B virusLithuaniaMiddle AgedSeasonsVaccinationVaccine EfficacyYoung AdultInfluenza VaccinesHospital surveillanceInfluenzaTest-negative designVaccine effectiveness

Identifiers

PMID37046288
PMCPMC10091321
OpenAlexW4365145362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.